Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.62 |
| ▸ | BRD4 | O60885 | 3/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | IL1B | P01584 | 1/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.58 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628170 | 1.00 | CRBN (0.62) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL19611888 | 0.94 | CRBN (0.55) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL19612074 | 0.94 | CRBN (0.55) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL22464461 | 0.94 | CRBN (0.60) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL464519 | 0.94 | CRBN (0.60) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL23772949 | 0.93 | CRBN (0.59) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL29137874 | 0.93 | CRBN (0.59) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL22464808 | 0.93 | CRBN (0.59) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL20362334 | 0.93 | CRBN (0.59) | CRBNBRD4IKZF3IKZF1TNF | |
| SCHEMBL22464605 | 0.92 | CRBN (0.64) | CRBNBRD4IKZF3IKZF1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| CN-111205282-B | ER protein modulators and uses thereof | 上海科技大学 | 2023-12-01 | — | — | CN | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| CN-110240629-B | Protein degradation targeting BCR-ABL compound and antitumor application thereof | 上海科技大学 | 2023-10-03 | — | — | CN | disclosed |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | SHANGHAITECH UNIVERSITY (CN) | 2023-05-02 | — | — | US | disclosed |
| US-20220135589-A1 | TARGETED UBIQUITINATION DEGRADATION BRD4 PROTEIN COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20220016102-A1 | ER PROTEIN REGULATORS AND USE THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-109912655-B | ALK protein degradation agent and anti-tumor application thereof | 上海科技大学 | 2021-12-10 | — | — | CN | disclosed |
| EP-3919127-A1 | TARGETED UBIQUITINATION DEGRADATION BRD4 PROTEIN COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2021-12-08 | — | — | EP | disclosed |
| US-20210085700-A1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-3725771-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2020-10-21 | — | — | EP | disclosed |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2020-10-01 | — | — | US | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-111205282-A | ER protein modulators and uses thereof | 上海科技大学 | 2020-05-29 | — | — | CN | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056510-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3035938-A1 | TARGETED THERAPEUTICS | Synta Pharmaceuticals Corp. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015038649-A1 | TARGETED THERAPEUTICS | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135589-A1 | TARGETED UBIQUITINATION DEGRADATION BRD4 PROTEIN COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BRD4, SUMO1, STUB1 | CRBN 761/4885BRD4 1/4885IKZF3 441/4885 |
| US-20210085700-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | CRBN 2162/4885BRD4 344/4885IKZF3 2282/4885 |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | ADRM1, VHL, MDM2 | CRBN 6/4885BRD4 2132/4885IKZF3 1051/4885 |
| US-20220016102-A1 | ER PROTEIN REGULATORS AND USE THEREOF | ESR2, ESRRG, ESRRA | CRBN 18/4885BRD4 1207/4885IKZF3 1264/4885 |
| US-11639343-B2 | Compounds targeting and degrading BCR-ABL protein and its antitumor application | CRBN, VHL, CBL | CRBN 1/4885BRD4 1105/4885IKZF3 1017/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | CRBN 6/4885BRD4 2132/4885IKZF3 1051/4885 |
| US-20170056510-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | CRBN 2162/4885BRD4 344/4885IKZF3 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.